News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
439,219 Results
Type
Article (22391)
Company Profile (164)
Press Release (416664)
Section
Business (135056)
Career Advice (1053)
Deals (24575)
Drug Delivery (106)
Drug Development (53713)
Employer Resources (88)
FDA (10945)
Job Trends (10238)
News (229205)
Policy (20402)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (1141)
Accelerated approval (1)
Adcomms (17)
Allergies (53)
Alliances (37551)
ALS (54)
Alzheimer's disease (740)
Antibody-drug conjugate (ADC) (89)
Approvals (10961)
Artificial intelligence (214)
Autoimmune disease (13)
Automation (14)
Bankruptcy (209)
Best Places to Work (7888)
BIOSECURE Act (14)
Biosimilars (97)
Biotechnology (79)
Bladder cancer (32)
Brain cancer (19)
Breast cancer (141)
Cancer (1213)
Cardiovascular disease (115)
Career advice (865)
Career pathing (23)
CAR-T (61)
Cell therapy (191)
Cervical cancer (6)
Clinical research (44768)
Collaboration (612)
Compensation (177)
Complete response letters (22)
COVID-19 (1374)
CRISPR (30)
C-suite (162)
Cystic fibrosis (62)
Data (1240)
Decentralized trials (2)
Denatured (19)
Depression (28)
Diabetes (164)
Diagnostics (3996)
Digital health (13)
Diversity (7)
Diversity, equity & inclusion (26)
Drug discovery (79)
Drug pricing (110)
Drug shortages (31)
Duchenne muscular dystrophy (58)
Earnings (49381)
Editorial (31)
Employer branding (10)
Employer resources (81)
Events (63497)
Executive appointments (512)
FDA (11719)
Featured Employer (29)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (454)
Gene editing (61)
Generative AI (22)
Gene therapy (170)
GLP-1 (601)
Government (2235)
Grass and pollen (2)
Guidances (30)
Healthcare (10085)
Huntington's disease (14)
IgA nephropathy (18)
Immunology and inflammation (78)
Indications (18)
Infectious disease (1467)
Inflammatory bowel disease (94)
Inflation Reduction Act (8)
Influenza (31)
Intellectual property (59)
Interviews (143)
IPO (10057)
IRA (45)
Job creations (2663)
Job search strategy (765)
Kidney cancer (7)
Labor market (21)
Layoffs (288)
Leadership (17)
Legal (4734)
Liver cancer (34)
Lung cancer (183)
Lymphoma (89)
Machine learning (2)
Management (32)
Manufacturing (236)
MASH (46)
Medical device (7823)
Medtech (7826)
Mergers & acquisitions (14891)
Metabolic disorders (507)
Multiple sclerosis (46)
NASH (20)
Neurodegenerative disease (47)
Neuropsychiatric disorders (21)
Neuroscience (1049)
NextGen: Class of 2025 (4012)
Non-profit (1695)
Northern California (1357)
Now hiring (22)
Obesity (307)
Opinion (202)
Ovarian cancer (37)
Pain (75)
Pancreatic cancer (47)
Parkinson's disease (87)
Partnered (13)
Patents (156)
Patient recruitment (65)
Peanut (27)
People (40817)
Pharmaceutical (79)
Pharmacy benefit managers (21)
Phase I (13920)
Phase II (18924)
Phase III (15301)
Pipeline (702)
Podcasts (72)
Policy (105)
Postmarket research (1718)
Preclinical (5015)
Press Release (43)
Prostate cancer (72)
Psychedelics (18)
Radiopharmaceuticals (186)
Rare diseases (255)
Real estate (4005)
Recruiting (31)
Regulatory (14748)
Reports (26)
Research institute (1198)
Resumes & cover letters (166)
Rett syndrome (2)
RNA editing (1)
RSV (24)
Schizophrenia (56)
Series A (82)
Series B (47)
Service/supplier (12)
Sickle cell disease (37)
Southern California (1247)
Special edition (15)
Spinal muscular atrophy (114)
Sponsored (24)
Startups (2436)
State (2)
Stomach cancer (9)
Supply chain (61)
The Weekly (50)
United States (13175)
Vaccines (321)
Venture capitalists (28)
Webinars (12)
Weight loss (238)
Women's health (24)
Worklife (11)
Date
Last 7 days (371)
Last 30 days (1622)
Last 365 days (22413)
2025 (5257)
2024 (23450)
2023 (26157)
2022 (34489)
2021 (37182)
2020 (36157)
2019 (30393)
2018 (23052)
2017 (22450)
2016 (21223)
2015 (24265)
2014 (18899)
2013 (16084)
2012 (17242)
2011 (17451)
2010 (15659)
Location
Africa (490)
Alabama (30)
Alaska (2)
Arizona (103)
Arkansas (9)
Asia (29685)
Australia (3870)
California (3212)
Canada (1280)
China (350)
Colorado (167)
Connecticut (147)
Delaware (99)
Europe (63457)
Florida (564)
Georgia (137)
Idaho (51)
Illinois (356)
India (21)
Indiana (255)
Iowa (6)
Japan (117)
Kansas (75)
Kentucky (22)
Louisiana (4)
Maine (26)
Maryland (470)
Massachusetts (2498)
Michigan (135)
Minnesota (293)
Mississippi (2)
Missouri (55)
Montana (25)
Nebraska (18)
Nevada (29)
New Hampshire (43)
New Jersey (1138)
New Mexico (25)
New York (881)
North Carolina (661)
North Dakota (7)
Northern California (1357)
Ohio (130)
Oklahoma (8)
Oregon (29)
Pennsylvania (729)
Puerto Rico (10)
Rhode Island (19)
South America (766)
South Carolina (15)
South Dakota (1)
Southern California (1247)
Tennessee (61)
Texas (488)
Utah (90)
Virginia (105)
Washington D.C. (48)
Washington State (280)
West Virginia (2)
Wisconsin (49)
439,219 Results for "catalent pharma solutions".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Catalent Announces New Board Appointments
February 20, 2025
·
4 min read
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
Deals
Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena
European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.
October 14, 2024
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
·
2 min read
·
Tristan Manalac
Editorial
Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work
With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
November 8, 2024
·
4 min read
·
Greg Slabodkin
Manufacturing
Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector
Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.
November 13, 2024
·
4 min read
·
Ben Hargreaves
Mergers & Acquisitions
Pharma Has Kept M&A Spending Small This Year, With Just One Deal Topping $5B
By far, the largest acquisition of 2024 was Novo Holdings’ yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.
December 11, 2024
·
4 min read
·
Annalee Armstrong
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form category
March 24, 2025
·
2 min read
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
1 of 43,922
Next
